Apr 1, 2013
By:
Ben Comer
Do Big Pharma dollars make physicians lousy caregivers?
|
|
Mar 1, 2013
By:
Ben Comer
In 2012, Merck's diabetes franchise became the highest-selling product family in its 122-year history.
|
Feb 1, 2013
By:
Ben Comer
After years of asking questions, the National Highway Traffic Safety Administration (NHTSA)is moving closer to a protocol "for assessing the driving-impairment risks of drugs". Ben Comer reports.
|
|
Jan 1, 2013
By:
Ben Comer
Compliance officers have risen into management's highest ranks, by choice in some organizations, and by government decree in others. Either way, their importance as a strategic partner can hardly be understated.
|
|
Dec 1, 2012
By:
Ben Comer
Ben Comer profiles 10 innovative technologies designated as new and revolutionary tools for the treatment of disease and disability.
|
|
Nov 1, 2012
By:
Ben Comer
Is the 'lost decade' of declining pipeline productivity finally over? Our annual survey of analyst assessments of the state of drug development suggests so...
|
|
Oct 1, 2012
By:
Ben Comer
Ideology, politics, and a stilted political debate may be causing pharma to overlook the potential of emerging stem cell therapies in fostering a new generation of cures.
|
Oct 1, 2012
By:
Ben Comer
A comparative effectiveness study on the two presidential candidates.
|
Sep 1, 2012
By:
Ben Comer
Specialized knowledge about disease and treatment is no longer the exclusive province of practicing physicians. Patient voices are increasing in volume, along with their roles in treatment decisions.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
